<- All drugs

Pramlintide

DISCONTINUED

Synthetic amylin analogue

graded results

ongoing records

effect domains

Evidence spread

High evidence 5Moderate evidence 0Low evidence 0Very low evidence 1

Pramlintide has a discontinued status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

DISCONTINUED United States; Type 1 and type 2 diabetes as an adjunct to mealtime insulin; Subcutaneous injection; as of 2026-07-13. US Food and Drug Administration openFDA

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Pramlintide DISCONTINUED

weight-loss Decrease

High evidence

Modest weight loss vs weight gain on insulin alone

Hollander PA, Levy P, Fineman MS, et al. 'Pramlintide as an adjunct to insulin therapy im... Source

PopulationT2D on mealtime insulin, FDA registration trials

Fundingindustry - Amylin Pharmaceuticals (pramlintide developer)

Comparatorsplacebo + insulin

Pramlintide DISCONTINUED

weight-loss Decrease

Very low evidence

Pramlintide, the first approved amylin analogue (US 2005), used as adjunct to insulin in type 1 and insulin-treated type 2 diabetes, produces modest HbA1c reductions...

Pramlintide (Symlin) approval and reviews; DrugBank DB01278; Vascular Health Risk Manag r... Source

Full findingPramlintide, the first approved amylin analogue (US 2005), used as adjunct to insulin in type 1 and insulin-treated type 2 diabetes, produces modest HbA1c reductions and weight loss (reported up to ~1.6 kg). Acts centrally (area postrema) to induce satiety, suppress prandial glucagon, slow gastric emptying and reduce prandial hyperglycaemia.

Populationadults with type 1 and insulin-treated type 2 diabetes (approved adjunct-to-insulin indication)

Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)

Comparatorsplacebo/insulin alone

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Pramlintide DISCONTINUED

glycaemic Decrease

High evidence

Modest HbA1c reduction as mealtime-insulin adjunct in T1D/T2D

SYMLIN (pramlintide acetate) FDA label, 2015 Source

PopulationT1D/T2D on mealtime insulin, FDA registration trials, ≥6 mo, RCT placebo-controlled

Fundingregulatory agency (FDA/EMA/MHRA/WHO)

Comparatorsplacebo + insulin

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Pramlintide DISCONTINUED

pharmacology Not directional

High evidence

Synthetic human amylin analogue; slows gastric emptying, suppresses glucagon, promotes satiety; t.i.d. mealtime dosing

SYMLIN FDA label 2015 Source

PopulationPharmacology / label

Fundingregulatory agency (FDA/EMA/MHRA/WHO)

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Pramlintide DISCONTINUED

safety-other Increase

High evidence

Boxed warning for insulin-induced severe hypoglycaemia; requires mealtime-insulin dose reduction

SYMLIN FDA label 2015 Source

PopulationT1D/T2D on mealtime insulin

Fundingregulatory agency (FDA/EMA/MHRA/WHO)

Comparatorsplacebo + insulin

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Pramlintide DISCONTINUED

Stomach and gut Increase

High evidence

Nausea most common AE; slows gastric emptying

SYMLIN FDA label 2015 Source

PopulationT1D/T2D registration trials

Fundingregulatory agency (FDA/EMA/MHRA/WHO)

Comparatorsplacebo + insulin